Rationale and design of Dapagliflozin vErsus SacubiTrIl-valsartaN therapY in Heart Failure with reduced ejection fraction (DESTINY-HF): a pragmatic randomised controlled trial protocol

Rationale and design of Dapagliflozin vErsus SacubiTrIl-valsartaN therapY in Heart Failure with reduced ejection fraction (DESTINY-HF): a pragmatic randomised controlled trial protocol

BackgroundHeart failure affects almost 64 million people, with more than half of it constituting heart failure with reduced ejection fraction (HFrEF). Angiotensin receptor-neprilysin inhibitors (ARNI) and sodium-glucose cotransporter-2 (SGLT2) inhibitors (SGLT2i) are in the first line for HFrEF, but...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ open 2024-10, Vol.14 (10), p.e089562
Hauptverfasser: Tiwari, Krishna, Deora, Surender, Choudhary, Rahul, Kaushik, Atul, Dwivedi, Pradeep, Singh, Surjit, Ambwani, Sneha, Midha, Naresh, Shukla, Ravindra, Sankanagoudar, Shrimanjunath, Shamim, Muhammad Aaqib, Tiwari, Vikas Kumar, Yadav, Isha, Dodiya, Rakesh, Varthya, Shoban Babu
Format: Artikel
Sprache:eng
Schlagworte:
Aminobutyrates - therapeutic use
Angiotensin Receptor Antagonists - therapeutic use
Antidiabetics
Benzhydryl Compounds - therapeutic use
Biomarkers
Biphenyl Compounds - therapeutic use
CARDIOLOGY
Cardiovascular Medicine
Decision making
Drug Combinations
Drugs
Echocardiography
Ejection fraction
Glucosides - therapeutic use
Heart failure
Heart Failure - drug therapy
Heart Failure - physiopathology
Hospitalization
Humans
Male
Medical prognosis
Meta-analysis
Mortality
Natriuretic Peptide, Brain - blood
Patients
Peptide Fragments
Protocol
Quality of life
Randomized Controlled Trials as Topic
Research Design
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Stroke Volume
Tetrazoles - therapeutic use
Valsartan - therapeutic use
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BackgroundHeart failure affects almost 64 million people, with more than half of it constituting heart failure with reduced ejection fraction (HFrEF). Angiotensin receptor-neprilysin inhibitors (ARNI) and sodium-glucose cotransporter-2 (SGLT2) inhibitors (SGLT2i) are in the first line for HFrEF, but no head-to-head trials are available. Moreover, growth differentiation factor-15 (GDF-15) has been demonstrated as a promising prognostic marker, specifically for HFrEF, but has not been explored much.MethodsThis pragmatic randomised controlled trial recruits 100 patients with HFrEF (ejection fraction
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2024-089562